Expand all sections

Marstacimab

Extended indication

Indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A or haemophil

Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Marstacimab
Domain

Cardiovascular diseases
Reason of inclusion

New medicine (specialité)
Main indication

Other medication for cardiovascular diseases
Extended indication

Indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A or haemophilia B.
Manufacturer

Pfizer

Registration

Registration route

Centralised (EMA)
Submission date

October 2023
Expected Registration

November 2024
Orphan drug

No
Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet
References 
NCT03938792

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.